- Tous > Medicine Access and Rational Use > Pricing
- Tous > Medicine Access and Rational Use > Rational Use
- Tous > Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Mots-clés > antiviral therapy
- Mots-clés > chronic diseases
- Mots-clés > health technology assessment (HTA)
- Mots-clés > hepatitis C
- Mots-clés > hepatitis C (HCV) – prevention and control, diagnosis and drug therapy
- Mots-clés > HIV/HCV coinfection
- Mots-clés > Intellectual Property Rights (IPR)
- Mots-clés > new medicines - prices, costs and affordability
- Mots-clés > patents
- Mots-clés > prices / pricing policy
(2017; 23 pages)
The WHO Western Pacific Region has had much success in prevention of hepatitis, in particular hepatitis B through immunization. However, there is a substantial burden of people chronically infected with hepatitis B and C who have little access to treatment. In particular, new hepatitis C direct-acting antivirals (DAAs) remain expensive and are a barrier to access to treatment for all who need it.
The Informal Consultation on Access to Hepatitis Medicines in Upper-Middle- and High-Income Countries was held at the WHO Regional Office for the Western Pacific in Manila, Philippines from 21 to 22 August 2017. Presentations and discussions on regional and global approaches to dealing with intellectual property rights, financing, drug pricing, health technology assessment, and research and development of treatments for hepatitis were part of the agenda.
Participants agreed on ways forward, including consideration of joint negotiation for medicines in the Region, greater sharing of pricing information and negotiation strategies, monitoring of real world efficacy of new direct-acting antivirals, capacity-building, and platforms for information sharing.